

SEQUENCE LISTING

<110> LINTNER, KARL
GABRIELE, DENISE E.

<120> COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS
OF CERAMIDES AND POLYPEPTIDES

<130> SEDERM 3.0-002

<140>

<141>

<150> FR 03 05707

<151> 2003-05-12

<160> 13

<170> PatentIn Ver. 3.2

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> see specification as filed for detailed description of lipid
group attachments and preferred embodiments

<400> 1

Val Gly Val Ala Pro Gly
1 5

<210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> see specification as filed for detailed description of lipid
group attachments and preferred embodiments

<400> 2

Lys Thr Thr Lys Ser
1 5

<210> 3
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
 <223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 3
 Gly Gln Pro Arg
 1

<210> 4
 <211> 12
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Formula sequence

<220>
 <221> MOD_RES
 <222> (1)..(3)
 <223> Variable amino acid or amino acid derivative; this region may encompass 0-3 amino acids; see specification as filed for detailed description of R-group substitutions and preferred embodiments

<220>
 <221> MOD_RES
 <222> (10)..(12)
 <223> Variable amino acid or amino acid derivative; this region may encompass 0-3 amino acids; see specification as filed for detailed description of R-group substitutions and preferred embodiments

<400> 4
 Xaa Xaa Xaa Val Gly Val Ala Pro Gly Xaa Xaa Xaa
 1 5 10

<210> 5
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> see specification as filed for detailed description of lipid
group attachments and preferred embodiments

<220>
<221> MOD_RES
<222> (5)
<223> Met or Leu

<400> 5
Tyr Gly Gly Phe Xaa
1 5

<210> 6
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> see specification as filed for detailed description of lipid
group attachments and preferred embodiments

<400> 6
Leu Gly Leu Ala Pro Leu
1 5

<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<223> see specification as filed for detailed description of lipid
group attachments and preferred embodiments

<400> 7
Ala Val Gly Val Ala Pro Gly
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 8

Ala Val Gly Val Ala Pro Gly Leu
1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of preferred embodiments

<400> 9

Leu Gly Val Ala Pro Ala
1 5

<210> 10

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 10

Val Gly Leu Gly Pro Gly
1 5

<210> 11

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of lipid group attachments and preferred embodiments

<400> 11

Ile Ala Ile Ala Pro Gly

1

5

<210> 12

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of preferred embodiments

<400> 12

Ile Ala Val Val Gly Ala Pro Gly Ala

1

5

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<223> see specification as filed for detailed description of preferred embodiments

<400> 13

Ser Val Gly Val Ala Pro Gly

1

5